SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-17-018892
Filing Date
2017-11-09
Accepted
2017-11-09 16:08:25
Documents
74
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20170930_10q.htm 10-Q 1121969
2 EXHIBIT 31.1 ex_99211.htm EX-31.1 10381
3 EXHIBIT 31.2 ex_99212.htm EX-31.2 10394
4 EXHIBIT 32.1 ex_99213.htm EX-32.1 4869
5 EXHIBIT 32.2 ex_99214.htm EX-32.2 5152
  Complete submission text file 0001437749-17-018892.txt   7095556

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT navb-20170930.xml EX-101.INS 1586926
7 XBRL TAXONOMY EXTENSION SCHEMA navb-20170930.xsd EX-101.SCH 64488
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20170930_cal.xml EX-101.CAL 65143
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20170930_def.xml EX-101.DEF 534332
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20170930_lab.xml EX-101.LAB 413670
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20170930_pre.xml EX-101.PRE 553081
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 171190866
SIC: 2835 In Vitro & In Vivo Diagnostic Substances